Skip to search formSkip to main contentSkip to account menu

FCE 24517

Known as: FCE-24517 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tallimustine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
FCE 24517-resistant MCF-7 human breast cancer cell line: selection and characterization.
We have developed a stable line of the human breast carcinoma cell line MCF-7 by in vitro continuous exposure to increasing… 
1998
1998
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
Tallimustine [PNU 152241 (FCE 24517)] is a synthetic derivative of the DNA minor groove binder distamycin A, in which the NH2… 
1996
1996
Backbone and benzoyl mustard carrying moiety modifies DNA interactions of distamycin analogues.
Alkylating distamycin derivative FCE-24517 (l) is the prototype of a novel class of alkylating agents. In the present study we… 
1994
1994
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
The role of alkylation of the N3 position of adenine in the cytotoxicity of alkylating agents in mammalian cells is still… 
1993
1993
Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to dna‐interacting anti‐neoplastic agents
Intracellular glutathione (GSH) content was measured by flow cytometry using monochlorobimane (mBCI) and by the enzymatic assay… 
1993
1993
The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)